Fig. 8

Validation of drug targets of proteomics and network pharmacology with western blot. A Western blot images of PIKfyve, AFF4, Amotl2, and GLP1R in the lung tissue. B–E Data were expressed as the expression ratio of PIKfyve/β-actin, AFF4/β-actin, Amotl2/β-actin, and GLP1R/β-actin (n = 3 per group). F Western blot images of HSP90AA1, MMP1, TGF-β1, JUN, P53, p-Akt, Akt, p-STAT3 and STAT3 in the lung tissue. G–M: Data were expressed as the expression ratio of HSP90AA1/β-actin, MMP1/β-actin, TGF-β1/β-actin, JUN/β-actin, P53/β-actin, p-Akt/Akt, and p-STAT3/STAT3 (n = 3 per group).^*P < 0.05, ^**P < 0.01 compared with CC group; ^#P < 0.05, ^##P < 0.01 compared with PF group. CC: control group, PF bleomycin-induced PF group, GH GHSPT treated bleomycin-induced PF group, GHSPT ginseng honeysuckle superfine powdered tea, PF pulmonary fibrosis